984 reports of this reaction
1.5% of all LENVATINIB reports
#15 most reported adverse reaction
HYPOTHYROIDISM is the #15 most commonly reported adverse reaction for LENVATINIB, manufactured by Eisai Inc.. There are 984 FDA adverse event reports linking LENVATINIB to HYPOTHYROIDISM. This represents approximately 1.5% of all 64,104 adverse event reports for this drug.
Patients taking LENVATINIB who experience hypothyroidism should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPOTHYROIDISM is a less commonly reported adverse event for LENVATINIB, but still significant enough to appear in the safety profile.
In addition to hypothyroidism, the following adverse reactions have been reported for LENVATINIB:
The following drugs have also been linked to hypothyroidism in FDA adverse event reports:
HYPOTHYROIDISM has been reported as an adverse event in 984 FDA reports for LENVATINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPOTHYROIDISM accounts for approximately 1.5% of all adverse event reports for LENVATINIB, making it a notable side effect.
If you experience hypothyroidism while taking LENVATINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.